Tel: 123.456.7890
The Team
Shuang Liu, PhD, Founder & CEO
A scientist, drug developer, and biotech entrepreneur with 25+ years of experience spanning small-molecule discovery, translational development, company building, financing, licensing, and partnering. She has secured millions of dollars in funding for ConSynance, advanced CSTI-500 into Phase 2 development for Prader-Willi Syndrome, and established a strategic partnership with Harmony Biosciences for CSTI-100. She is a co-inventor on more than 30 patent families.
Shuang Liu | LinkedIn
Dejian Xie, PhD, President & General Manager, ConSynance Hong Kong
A biopharmaceutical executive with extensive cross-border leadership experience across China, Singapore and the United States. His experience spans drug discovery, CMC, early clinical development, company operations, financing, and strategic execution. He previously served as co-founder and COO of Xiling Lab of China, where he helped build the company and secure series A financing.
Jill Rasmussen, MD, Acting Medical Director
A medical professional with 30+ years experience in global drug development in psychiatric and neurological indications, including work with regulatory agencies. Decades' clinical practice in mental health, intellectual disability and dementia.
Lois Rosenberger, PhD, Director of Regulatory and Clinical Operation (consulting)
Founder of LBRIA Regulatory and Clinical Consulting Services. 30+ years of regulatory, quality assurance, and 20+ years of experience in managing clinical trials including for PWS. Lois held regulatory leadership positions at Kendle CRO, Marion-Merrell Dow, and P&G.
Lois Rosenberger | LinkedIn
Sarah Sheldrick, PhD, VP, Translational Research
Neuroscience researcher experienced in translational research, including molecular and imaging biomarker qualification, mechanistic research, and clinical trial design and management. She earned a PhD in Psychological Medicine from King’s College London and served as Biomarker Team Leader for the Translational Neuroscience and Dementia Research group at the University of Oxford.
Sarah Sheldrick | LinkedIn
John Maki, Strategic Advisor
A biotechnology executive, investor, and board leader with extensive experience in drug development, corporate strategy, venture capital, particularly in rare diseases. His experience includes Managing Director at TDI and Audax Group, and Principal at Bain Capital. He is the chair of BioNJ’s Digital/AI Committee. He advises ConSynance on strategic planning, investment positioning, and long-term development.
John Maki | LinkedIn